Amycretin reddit: Novo Nordisk’s Answer to Reta?

Amycretin Reddit discussion treats Novo Nordisk’s GLP-1/amylin drug as a possible answer to Retatrutide, but the conversation is ahead of the user evidence. Randomized human trials show substantial early weight loss with injected and oral forms; Phase 3 has started, no head-to-head retatrutide result exists, and amycretin is not FDA-approved.

Why is amycretin suddenly showing up on Reddit?

Amycretin is drawing attention because one molecule activates GLP-1 and amylin pathways, Novo is developing both a weekly injection and a daily tablet, and the early weight-loss number was large. Discussion on r/Peptides and r/Retatrutide repeatedly circles availability, whether the pill can compete with injections, and whether Novo has found its “reta answer.”

The useful catch is that this is still mostly pipeline talk. Amycretin, now called zenagamtide, has scattered trial-participant anecdotes but nothing like the large volume of user diaries around approved GLP-1 drugs or gray-market retatrutide. Reddit is watching the starting gun, not reporting from mile 20. The amycretin evidence profile covers the molecule separately from the conversation around it.

What do the amycretin results actually show?

Amycretin results show a strong early human signal, graded human RCT, helped in our profile, but the famous 24.3% figure needs its full label. In a randomized Phase 1b/2a study, the model-estimated mean loss at 36 weeks was 24.3% with 60 mg weekly versus 1.1% with placebo. The 20 mg group reached 22.0% versus a 1.9% placebo gain (Dahl et al., PMID 40550231).

That headline did not come from a large obesity trial. The 60 mg dose-escalation part had 22 participants: 17 received amycretin, and 10 of those 17 withdrew. Across the 125-person study, 33% withdrew; the paper reports that 59% of discontinuations were for reasons unrelated to treatment-emergent adverse events. The number is real. Treating it as a settled average for future patients is not.

Is oral amycretin better than the weekly injection?

Oral amycretin is the convenience story, not yet the proven winner. A randomized first-in-human Phase 1 study tested once-daily tablets for up to 12 weeks. The longer oral groups lost an average 10.4% with 50 mg and 13.1% with two 50 mg tablets, versus 1.2% with placebo (Gasiorek et al., PMID 40550229).

The injected and oral amycretin results cannot be ranked cleanly. The injection study ran as long as 36 weeks; the oral study ran 12 weeks and treated weight change as exploratory. Different durations, doses, formulations, and participant groups make “pill versus shot” arithmetic look tidier than the science. Novo is developing both forms, which makes route choice a real future question rather than a result Reddit can settle today.

How does amycretin vs retatrutide really compare?

Amycretin vs retatrutide is a mechanism comparison and a cross-trial guess, because no published head-to-head trial has compared them. Amycretin combines GLP-1 and amylin activity in one peptide. Retatrutide activates GLP-1, GIP, and glucagon receptors. More receptor names do not produce a winner by simple addition.

Reddit often lines up amycretin’s 24.3% at 36 weeks beside a retatrutide result from a different trial and declares a race. That skips study size, treatment length, dose escalation, withdrawal, population, and analysis method. The fair conclusion is narrower: both produced substantial weight loss in randomized human studies, retatrutide has later-stage results, and amycretin’s Phase 3 obesity program now has to show whether the early signal survives at scale.

What side effects does Reddit tend to underplay?

Amycretin’s clearest safety signal is gastrointestinal intolerance, especially nausea, vomiting, and diarrhea, with events becoming more frequent at higher doses. Most events in the published trials were mild or moderate, but “mostly mild” and “frequent” belong together. The injected study also had enough withdrawals that tolerability cannot be reduced to a reassuring adjective.

In the oral study, 89 of 144 participants reported a treatment-emergent adverse event. Gastrointestinal problems affected 72 of those 89 people and accounted for 180 of 364 recorded events. Reddit can flag what an upset stomach feels like; early trials are better for counting it. Long-term safety and uncommon harms remain less certain because the published studies were short, small, single-center trials sponsored by Novo Nordisk.

When could amycretin become available?

Amycretin has no verified approval date, and any confident launch countdown is speculation. The recruiting Phase 3 AMAZE 1 obesity trial started on February 24, 2026, plans to enroll 1,150 participants, and lists June 2029 as its estimated primary completion (NCT07339423). Other AMAZE studies cover weight maintenance and obesity-related conditions.

As of July 2026, neither amycretin nor zenagamtide appears on the FDA’s 2026 novel drug approvals. There is no approved amycretin pen, tablet, dose, or U.S. label. A product advertised online under that name is not authenticated by the clinical evidence. Phase 3 means Novo is making the serious bet; it does not mean the finish date has been booked.

Where is Reddit right — and where is it off?

Reddit is right that novo amycretin has a real randomized human weight-loss signal, that a daily oral peptide could matter, and that GLP-1 plus amylin is a serious design rather than a renamed copy of retatrutide. Cagrilintide helps explain the amylin half of that interest. Reddit is also right to watch Phase 3 rather than dismiss an early program.

Reddit is off when the 24.3% estimate becomes a typical outcome, oral and injectable results become interchangeable, or amycretin is crowned over retatrutide without a direct trial. The amycretin reddit posts are anecdotal; the efficacy signal is human RCT evidence. Those tiers can sit on the same page, but they cannot do each other’s jobs. Our evidence-grading method shows why that distinction matters.